Advertisement

Definition and Changes in Nomenclature of Hepatic Encephalopathy

  • Chathur Acharya
  • Jasmohan S. Bajaj
Chapter

Abstract

Hepatic encephalopathy is by definition a brain dysfunction caused by liver insufficiency and/or PSS; it manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. It is related to brain dysfunction from a combination of ammonia, endotoxins, and other neurotoxins with the end result being neuro-inflammation. Given the vast spectrum of manifestations, the nomenclature is detailed with multiple components to address aspects such as etiology, severity, temporality, and precipitating factor. From a clinical perspective it is important to understand each aspect in order to determine the etiology of the episode and to plan for prevention of recurrence. A strong initial workup based on the nomenclature will ensure a more successful outcome for the patient in the long run.

Keywords

Overt hepatic encephalopathy Covert hepatic encephalopathy West Haven grade 

References

  1. 1.
    Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72(4 Pt 1):573–83.PubMedGoogle Scholar
  3. 3.
    Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY, International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33(7):739–47.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PloS One. 2016;11(1):e0146076.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Reuter B, Walter K, Bissonette J, Leise MD, Lai J, Tandon P, Kamath PS, Biggins SW, Rose CF, Wade JB, Bajaj JS. Assessment of the spectrum of hepatic encephalopathy: a multi-center study. Liver Transpl. 2018; doi:  10.1002/lt.25032. [Epub ahead of print] PMID: 29457869CrossRefPubMedGoogle Scholar
  6. 6.
    Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transplant. 2007;13(10):1366–71.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology, Hepatology and NutritionVirginia Commonwealth University and McGuire VA Medical CenterRichmondUSA

Personalised recommendations